title: [Position of surveillance therapy in clinical stage I testicular non-seminoma].
abstract: Since the initiation of a 'surveillance' therapy the role of retroperitoneal lymph node dissection as standard treatment in the management of patients with clinical stage I nonseminomatous germ cell testicular tumor (NSGCTT) continues to be debated. Noninvasive staging techniques (CT scans, lymphography, ultrasound and serologic tumor markers) help to identify more accurately patients with distant metastases. 'Surveillance' alone as a possible treatment modality following orchidectomy in selected patients with clinical stage I NSGCTT requires cooperative and reliable patients. In our urological clinic surveillance alone is not justified any longer because of a noncompliance rate of 10% and a relapse rate of 30%, although the early detection of small-volume metastatic disease, lymphadenectomy and polychemotherapy result in a high rate of cure. Any patient should be excluded from 'wait and see' protocols if metastatic prognostic factors such as vascular infiltration of the primary tumor or local tumor stage greater than pT1 are identified.
authors.affiliation: Abteilung Urologie, Bundeswehrkrankenhaus Ulm.
authors.forename: W F
authors.initials: WF
authors.lastname: Thon
authors.forename: C
authors.initials: C
authors.lastname: Sparwasser
authors.forename: P
authors.initials: P
authors.lastname: Gilbert
authors.forename: J E
authors.initials: JE
authors.lastname: Altwein
mesh_terms: D014408:Biomarkers, Tumor / Q000032:analysis; D005500:Follow-Up Studies; D006801:Humans; D008197:Lymph Node Excision; D008207:Lymphatic Metastasis / Q000175:diagnosis*; D008297:Male; D009367:Neoplasm Staging; D009373:Neoplasms, Germ Cell and Embryonal / Q000473:pathology / Q000601:surgery*; D009919:Orchiectomy; D010349:Patient Compliance; D013736:Testicular Neoplasms / Q000473:pathology / Q000601:surgery*; D014057:Tomography, X-Ray Computed; D014463:Ultrasonography
chemical_list: D014408:Biomarkers, Tumor
vernacular_title: Stellenwert der Surveillance-Therapie beim nichtseminomatösen Hodentumor im klinischen Stadium I.